Brief: Clearside Biomedical Announces Approval Of Xipere® Suprachoroidal Treatment For Uveitic Macular Edema In Canada
23/07/2025 12:17
July 23 (Reuters) - Clearside Biomedical Inc CLSD.O: CLEARSIDE BIOMEDICAL ANNOUNCES APPROVAL OF XIPERE® SUPRACHOROIDAL TREATMENT FOR UVEITIC MACULAR EDEMA IN CANADA Source text: ID:nGNX6tkF37 Further company coverage: CLSD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearside Biomedical,
See all newsBrief: Clearside Biomedical Completes Financial Restructuring And Emerges From Chapter 11 With Steel Partners As Plan Sponsor
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Clearside Biomedical plunges after filing for Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials